Tariq Yousuf
Internal Medicine · Sherman, TXNPI 1730509472
Payments from drug & device makers
Across 314 payments — averaging $240.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$64K
- Philips North America LLC$3K
- Angiodynamics, Inc.$2K
- Abbott$1K
- Biotronik Inc.$982
- AOP Health US, LLC$527
- plus $4K from 29 others
What the payments were for
- Travel & lodging$3,44731%
- Food & beverage$7,08763%
- Education$6926%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 3 | $64,370 |
| Philips North America LLC | 71 | $2,764 |
| Angiodynamics, Inc. | 8 | $1,891 |
| Abbott | 23 | $1,096 |
| Biotronik Inc. | 71 | $982 |
| AOP Health US, LLC | 1 | $527 |
| Pfizer | 23 | $485 |
| Novartis | 22 | $417 |
| Terumo Medical Corporation | 3 | $338 |
| Cardiovascular Systems Inc. | 9 | $301 |
| Medtronic(2 entities) | 2 | $265 |
| Cook Medical LLC | 2 | $237 |
| Merck | 12 | $235 |
| Johnson & Johnson | 11 | $207 |
| Boston Scientific | 9 | $182 |
| Astellas Pharma US Inc | 2 | $174 |
| E.r. Squibb & Sons, L.L.C. | 8 | $150 |
| Novo Nordisk | 6 | $124 |
| United Therapeutics Corporation | 1 | $120 |
| Atricure, Inc. | 2 | $108 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $104 |
| Cleerly, Inc. | 1 | $95 |
| AstraZeneca | 4 | $77 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Amarin Pharma, Inc. | 2 | $39 |
| Abiomed | 1 | $38 |
| Akebia Therapeutics Inc | 1 | $38 |
| Heartflow, Inc. | 1 | $32 |
| Silk Road Medical, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $18 |
| Baxter Healthcare | 1 | $18 |
| Cathworks, Inc. | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Cordis US CORP. | 1 | $15 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaCure 1470 Pro$1,779
- (9520) IGT Devices Undivided$1,324
- Rapiblyk$1,054
- GLIDESHEATH SLENDER$253
- HeartMate 3 Left Ventricular Dev$253
- Hi-Torque Balance guide wires$163
- Resolute$140
- Hi-Torque Iron Man guide wire$140
- Diamondback Peripheral$138
- Zilver PTX$128
- HawkOne$125
- ORENITRAM$120
- TYVASO$120
- REMODULIN$120
- Cook Medical Embolization$109
- (6554) Peripheral Vascular Undivided$106
How this compares
$75,566 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 284 | $247,807 |
| XareltoRivaroxaban | 90 | $70,532 |
| Repatha SureclickEvolocumab | 38 | $24,120 |
| BrilintaTicagrelor | 37 | $23,389 |
| FarxigaDapagliflozin Propanediol | 20 | $20,476 |
| Ranolazine ErRanolazine | 74 | $5,376 |
| ClopidogrelClopidogrel Bisulfate | 512 | $4,283 |
| Rosuvastatin Calcium | 335 | $3,490 |
| Metoprolol Succinate | 391 | $3,401 |
| Midodrine Hcl | 15 | $2,133 |
| Flecainide Acetate | 21 | $1,452 |
| Atorvastatin Calcium | 229 | $1,427 |
| Amlodipine Besylate | 327 | $1,399 |
| Lisinopril | 162 | $1,216 |
| Furosemide | 217 | $1,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $485 | $247,807284 claims |
| Johnson & JohnsonXarelto | $207 | $70,53290 claims |
| AstraZenecaBrilinta, Farxiga | $77 | $43,86557 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Sherman
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.